Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations.
D001971:Bromocriptine / Q000627:therapeutic use; D004298:Dopamine / Q000502:physiology*; D004359:Drug Therapy, Combination; D006801:Humans; D008090:Lisuride / Q000627:therapeutic use; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000627:therapeutic use; D014191:Tranylcypromine / Q000627:therapeutic use
D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline; D001971:Bromocriptine; D014191:Tranylcypromine; D008090:Lisuride; D004298:Dopamine